Literature DB >> 8388742

Structure and function of the urokinase receptor.

L B Møller1.   

Abstract

The urokinase plasminogen activator receptor (u-PAR), present on the surface of a number of cell types, is a key component in the plasminogen activation system where it serves to localize and accelerate the activation cascade. In the present review, structural and functional aspects of u-PAR are discussed with special emphasis on newer findings. The structural features discussed include a repetitive domain structure with an NH2-terminal, ligand-binding domain, a membrane anchor of the GPI-type and high amounts of N-linked carbohydrate. The demonstration of a previously identified monocyte activation antigen, Mo3, as being identical with u-PAR, is described. Functional aspects include the ligand-binding process, the consequences of this binding process for the activation cascade system, the cleavage of u-PAR by u-PA itself, and the internalization of u-PA inhibitor complexes. Finally, a number of findings are discussed which support the view that u-PA/u-PAR are important components in degradation processes during cancer invasion. Immunocytochemistry and in situ hybridization studies have revealed complicated interplays between different cell types, specifically at the invasive front regions of tumours, with regard to these molecules, and in in vitro model systems for invasion the putative roles of the components have been studied.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388742

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  18 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

2.  The urokinase plasminogen activator receptor (UPAR) is preferentially induced by nerve growth factor in PC12 pheochromocytoma cells and is required for NGF-driven differentiation.

Authors:  R Farias-Eisner; L Vician; A Silver; S Reddy; S A Rabbani; H R Herschman
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

3.  Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).

Authors:  R Balabanov; D Lisak; T Beaumont; R P Lisak; P Dore-Duffy
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.

Authors:  D F Alonso; E F Farías; V Ladeda; L Davel; L Puricelli; E Bal de Kier Joffé
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Plasma glycosylphosphatidylinositol phospholipase D (GPI-PLD) and abdominal aortic aneurysm.

Authors:  Markus Lindqvist; Jonas Wallinder; Jörgen Bergström; Anders E Henriksson
Journal:  Int J Clin Exp Med       Date:  2012-08-20

6.  Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.

Authors:  M M Heiss; H Allgayer; K U Gruetzner; R Babic; K W Jauch; F W Schildberg
Journal:  Ann Surg       Date:  1997-12       Impact factor: 12.969

7.  Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.

Authors:  Kyung Hee Lee; Eun Young Choi; Myung Soo Hyun; Byung Ik Jang; Tae Nyeun Kim; Heon Ju Lee; Jong Yuel Eun; Hong Gin Kim; Sung Soo Yoon; Dong Sik Lee; Jung Hye Kim; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2007-11-09       Impact factor: 5.150

8.  Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Authors:  Elaine M Sloand; Loretta Pfannes; Phillip Scheinberg; Kenneth More; Colin O Wu; McDonald Horne; Neal S Young
Journal:  Exp Hematol       Date:  2008-10-26       Impact factor: 3.084

Review 9.  The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?

Authors:  Heike Allgayer; Julio A Aguirre-Ghiso
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

10.  siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.

Authors:  Ramesh Subramanian; Christopher S Gondi; Sajani S Lakka; Aman Jutla; Jasti S Rao
Journal:  Int J Oncol       Date:  2006-04       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.